Skip to main content
Erschienen in: International Cancer Conference Journal 2/2019

13.02.2019 | Case report

Acute arteritis after G-CSF administration

verfasst von: Yasuyuki Kinjo, Tomoko Kurita, Taeko Ueda, Seiji Kagami, Yusuke Matsuura, Kiyoshi Yoshino

Erschienen in: International Cancer Conference Journal | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Granulocyte colony-stimulating factor (G-CSF) is commonly used in clinical practice to accelerate neutropenia recovery after chemotherapy. G-CSF is a myeloid growth factor produced by monocytes, macrophages, fibroblasts and endothelial cells. Generally, aortitis and arteritis are not a known side effect of G-CSF and is thought to be extremely rare. Here, we present a case of a 77-year-old woman who underwent adjuvant chemotherapy (combined paclitaxel and carboplatin) for ovarian cancer, and then developed acute arteritis after receiving G-CSF. She developed grade 4 neutropenia on day 7 of the third chemotherapy cycle and received six G-CSF administrations. Two days after G-CSF administration, she came down with a high-grade fever that persisted for 2 weeks. Laboratory tests revealed a white blood cell count of 8700 UI, neutrophilic sequestration of 61.5%, and C-reactive protein of 8.43 mg/dl at the highest point of her fever. Considering that we were initially treating neutropenia, we diagnosed a bacterial infection, and she was treated with a course of antibiotics. However, her blood and urinalysis cultures were negative, and antibiotics were ineffective; thus, we performed a computed tomography scan to search for the cause of her persistent fever. The computed tomography scan showed remarkable thickness of the bilateral common carotid artery and the left subclavian artery consistent with arteritis. With cessation of the antibiotics course, she was followed closely without therapy, and her condition resolved in a few days. We conclude that G-CSF induced arteritis due to our exclusion of other probable etiologies.
Literatur
1.
Zurück zum Zitat D’Souza A, Jaiyesimi I, Trainor L et al (2008) Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 22(4):280–290CrossRefPubMed D’Souza A, Jaiyesimi I, Trainor L et al (2008) Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 22(4):280–290CrossRefPubMed
2.
Zurück zum Zitat McMullin MF, Finch MB (1995) Felty’s syndrome treated with rhG-CSF associated with flare of arthritis and skin rash. Clin Rheumatol 14(2):204–208CrossRefPubMed McMullin MF, Finch MB (1995) Felty’s syndrome treated with rhG-CSF associated with flare of arthritis and skin rash. Clin Rheumatol 14(2):204–208CrossRefPubMed
3.
Zurück zum Zitat Hayat SQ, Hearth-Holmes M, Wolf RE (1995) Flare of arthritis with successful treatment of Felty’s syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 14(2):211–212CrossRefPubMed Hayat SQ, Hearth-Holmes M, Wolf RE (1995) Flare of arthritis with successful treatment of Felty’s syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 14(2):211–212CrossRefPubMed
4.
Zurück zum Zitat Iking-Konert C, Ostendorf B, Foede M et al (2004) Granulocyte colony-stimulating factor induces disease flare in patients with antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 31(8):1655–1658PubMed Iking-Konert C, Ostendorf B, Foede M et al (2004) Granulocyte colony-stimulating factor induces disease flare in patients with antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 31(8):1655–1658PubMed
5.
Zurück zum Zitat Farhey YD, Herman JH (1995) Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty’s syndrome. J Rheumatol 22(6):1179–1182PubMed Farhey YD, Herman JH (1995) Vasculitis complicating granulocyte colony stimulating factor treatment of leukopenia and infection in Felty’s syndrome. J Rheumatol 22(6):1179–1182PubMed
6.
Zurück zum Zitat Vidarsson B, Geirsson AJ, Onundarson PT (1995) Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty’s syndrome. Am J Med 98(6):589–591CrossRefPubMed Vidarsson B, Geirsson AJ, Onundarson PT (1995) Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty’s syndrome. Am J Med 98(6):589–591CrossRefPubMed
8.
Zurück zum Zitat Rojo-Leyva F, Ratliff NB, Cosgrove DM et al (2000) Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. Arthritis Rheum 43(4):901–907CrossRefPubMed Rojo-Leyva F, Ratliff NB, Cosgrove DM et al (2000) Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. Arthritis Rheum 43(4):901–907CrossRefPubMed
9.
Zurück zum Zitat Darie C, Boutalba S, Fichter P et al (2004) Aortitis after G-CSF injections. Rev Med Interne 25(3):225–229CrossRefPubMed Darie C, Boutalba S, Fichter P et al (2004) Aortitis after G-CSF injections. Rev Med Interne 25(3):225–229CrossRefPubMed
10.
Zurück zum Zitat Adiga GU, Elkadi D, Malik SK et al (2009) Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Investig 29(12):821–825CrossRefPubMed Adiga GU, Elkadi D, Malik SK et al (2009) Abdominal aortitis after use of granulocyte colony-stimulating factor. Clin Drug Investig 29(12):821–825CrossRefPubMed
11.
Zurück zum Zitat Miller EB, Grosu R, Landau Z (2016) Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). Clin Rheumatol 35(6):1655–1657CrossRefPubMed Miller EB, Grosu R, Landau Z (2016) Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). Clin Rheumatol 35(6):1655–1657CrossRefPubMed
12.
Zurück zum Zitat Sloand EM, Kim S, Maciejewski JP et al (2000) Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95(7):2269–2274PubMed Sloand EM, Kim S, Maciejewski JP et al (2000) Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95(7):2269–2274PubMed
Metadaten
Titel
Acute arteritis after G-CSF administration
verfasst von
Yasuyuki Kinjo
Tomoko Kurita
Taeko Ueda
Seiji Kagami
Yusuke Matsuura
Kiyoshi Yoshino
Publikationsdatum
13.02.2019
Verlag
Springer Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 2/2019
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-018-00357-z

Weitere Artikel der Ausgabe 2/2019

International Cancer Conference Journal 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.